ESTRO 2024 - Abstract Book

S1593

Clinical - Lung

ESTRO 2024

2. Park, J.M., Wu, HG., Kim, H.J. et al. Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR. Radiat Oncol 14, 105 (2019). https://doi.org/10.1186/s13014-019-1314-0.

3. Munirathinam, N., & Pawaskar, P. (2019). Dosimetric comparison of flattened and flattening filter-free beams for liver stereotactic body irradiation in deep inspiration breath hold, and free breathing conditions. Journal of Radiotherapy in Practice, 18(2), 169-174. doi:10.1017/S146039691800064X

4. Silva Mendes, V., Nierer, L., Li, M. et al. Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer. Radiat Oncol 16, 133 (2021). https://doi.org/10.1186/s13014-021-01858-7.

5. Merna C, Rwigema JC, Cao M, Wang PC, Kishan AU, Michailian A, Lamb J, Sheng K, Agazaryan N, Low DA, et al. A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer. Med Dosim. 2016; 41:87 – 91.

6. Yadav P, et al. Dosimetric study for spine stereotactic body radiation therapy: magnetic resonance guided linear accelerator versus volumetric modulated arc therapy. Radiol Oncol. 2019; 53(3):362 – 8.

216

Digital Poster

Prediction of serum biomarkers for cognitive decline after PCI in lung cancer: an exploratory study

Haiyan Zeng 1,2 , Lizza Hendriks 3 , José José Belderbos 4 , Lloyd Brandts 5 , Inge Compter 2 , Ludwig Dubois 6 , Matthew Holt 7 , Ruud Houben 2 , Adrian Liston 8 , Sanne Schagen 9 , Xin Zhang 2 , Teresa Prezzemolo 10 , Dirk De Ruysscher 2 1 Cancer Center, West China Hospital, Sichuan University, Department of Radiation Oncology, Division of Thoracic Oncology, Chengdu, China. 2 GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Department of Radiation Oncology (Maastro), Maastricht, Netherlands. 3 GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Department of Pulmonary Diseases, Maastricht, Netherlands. 4 The Netherlands Cancer Institute, Radiation Oncology, Amsterdam, Netherlands. 5 Maastricht University Medical Center+, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, Netherlands. 6 GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, The M-Lab, Department of Precision Medicine,, Maastricht, Netherlands. 7 University of Porto, Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal. 8 University of Cambridge, Department of Pathology, University of Cambridge, United Kingdom. 9 The Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology, Amsterdam, Netherlands. 10 KU Leuven-University of Leuven, Department of Microbiology and Immunology, Leuven, Belgium

Purpose/Objective:

Neurocognitive decline is a concern for patients with small cell lung cancer (SCLC) who need prophylactic cranial irradiation (PCI). So far no reliable risk prediction model can predict neurocognitive decline after PCI. Evaluation of blood biomarkers that could be associated with neurocognitive decline after PCI is attractive, as blood samples are relatively easy to obtain and if validated, blood biomarkers would be very useful to screen patients who are at a